Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival

Glioblastoma (GBM) is the most malignant brain tumor where patients' survival is only 14.6 months, despite multimodal therapy with debulking surgery, concurrent chemotherapy and radiotherapy. There is an urgent, unmet need for novel, effective therapeutic strategies for this devastating disease...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Poli, Aurélie, Wang, Jian, Domingues, Olivia, Planagumà, Jesús, Yan, Tao, Rygh, Cecilie Brekke, Skaftnesmo, Kai Ove, Thorsen, Frits, McCormack, Emmet, Hentges, François, Pedersen, Paal Henning, Zimmer, Jacques, Enger, Per Øyvind, Chekenya, Martha
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2013
Konular:
Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3824525/
https://ncbi.nlm.nih.gov/pubmed/24127551
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller